Bridgeway Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Bridgeway Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$400K	Buy	71,873 +6,000	+9%	+$45.7K	0.01%	861
2025 Q4	$485K	Buy	65,873 +31,000	+89%	+$190K	0.01%	824
2025 Q3	$228K	Sell	34,873 -2,963	-8%	-$15.9K	﹤0.01%	991
2025 Q2	$163K	Buy	+37,836	New	+$186K	﹤0.01%	1001
2025 Q1	–	Sell	-15,967	Closed	-$162K	–	1222
2024 Q4	$162K	Hold	15,967	–	–	﹤0.01%	1042
2024 Q3	$199K	Sell	15,967 -1,666	-9%	-$20.7K	﹤0.01%	1069
2024 Q2	$229K	Buy	17,633 +5,000	+40%	+$82.8K	0.01%	1026
2024 Q1	$286K	Sell	12,633 -6,667	-35%	-$117K	0.01%	1047
2023 Q4	$250K	Hold	19,300	–	–	0.01%	1090
2023 Q3	$388K	Buy	+19,300	New	+$433K	0.01%	952

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Bridgeway Capital Management's KPTI Position: Q1 2026 in Review

Bridgeway Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 9.1% in Q1 2026, buying an estimated $45.7K and bringing the position to 71,873 shares worth $400K. The position accounts for 0.01% of the portfolio, ranked #861.

Bridgeway Capital Management first reported a position in KPTI in Q3 2023 and has held it in 10 quarters since. The position peaked at $485K in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Bridgeway Capital Management held 71,873 shares of Karyopharm Therapeutics worth $400K as of Q1 2026.
Bridgeway Capital Management bought 6,000 Karyopharm Therapeutics shares in Q1 2026, an estimated $45.7K.
Karyopharm Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #861 holding.
Bridgeway Capital Management first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 10 quarters since.
Bridgeway Capital Management's Karyopharm Therapeutics position peaked at $485K in Q4 2025.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.